Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Investor Presentation (November 2005)
35 slides from Neuren Pharmaceuticals's investor presentation, Dec 2, 2005
Slide 1: Neuren Pharmaceuticals Institutional Placement
_ (neuren ) pharmaces Neuren Pharmaceuticals Institutional Placement Raising $6.36 million November 2005
Slide 2: Important information
Important information The information contained it his document and otherwise disclosed to you by Patersons Securities Ltd or Neuren Pharmaceuticals Limited prior to a public announcement must be kept strictly confidential for the following reasons: in accordance with Section 1043A of the Corporatio
Slide 3: Agenda
Agenda ss Company Overview Lead Products - Glypromate® and NNZ 2566 Glypromate® Development Development Pipeline Commercialisation Strategy Board and Management Offer Details Conclusion o oN eo PF eR} Appendices : “- Gneuren hareaciannl
Slide 4: Corporate overview
Corporate overview Neuren is a drug development company targeting Neuronz Ltd: 124% brain repair& rescue, metabolism and cancer NZ Seed Fund Management Ltd: 41.4% Neuren’s lead products protect against brain damage Macquarie Bank Tech Funds: 9.6% Glypromate® has been accelerated into Phase-3 Pfizer
Slide 5: Investment highlights
Investment highlights Stage of Development Poised for Major Milestones Excellent Commercialisation Prospecis Glypromate® accelerated to Phase 3 in CY2006 ~ Multi-site international and domestic trials NNZ 2566 is entering Phase 1 in 1H CY2006 & Phase 2 in 2H CY2006 ~ Conducting in collaboration with
Slide 6: Investment highlights
Investment highlights Uniquely positioned to fund lis own Phase 3 Study Significant Market Opportunities Breadth and qualiiy Excellent Management Team of portfolio Altractively Priced . Very few Australian companies are in Phase 3 trials: Typically prohibitively expensive Neuren in close consultatio
Slide 7: Agenda
Agenda ss Company Overview Lead Products - Glypromate® and NNZ 2566 Glypromate® Development Development Pipeline Commercialisation Strategy Board and Management Offer Details Conclusion i Appendices : “- Gneuren hareaciannl
Slide 8: Repairing brain damage from aging and injury
Repairing brain damage from aging and injury BRAIN INJURY DISEASE = Brain cells die acutely = Stroke ~ No blood supply * Traumatic Brain Injury ~ Trauma (TBI) = Brain cells die chronically « Alzheimer’s Disease ~ Disease process =» Parkinson’s Disease ~ Agin ging = Memory Loss = Nervous tissue in th
Slide 9: Lead Products: Glypromate and NNZ-2566
Lead Products: Glypromate® and NNZ-2566 =» Neural repair agents face several challenges, including: ~ Blood-brain barrier prevents many molecules reaching the brain ~ Most brain injuries, such as stroke, are unscheduled ~ Several mechanisms by which cell death occurs 2 Neuren’s two lead compounds ad
Slide 10: Lead Products: Glypromate and NNZ-2566
Lead Products: Glypromate® and NNZ-2566 = NNZ-2566 is a modified version of Glypromate® with additional attractive characteristics including: 1. Longer Acting: Better treatment window 2. Oral bioavailability: Critical for chronic indications including Parkinson’s Disease, Alzheimer’s Disease and age
Slide 11: Agenda
Agenda ss Company Overview Lead Products - Glypromate® and NNZ 2566 Glypromate® Development Development Pipeline Commercialisation Strategy Board and Management Offer Details Conclusion i lS Appendices ‘e : “- Gneuren hareaciannl
Slide 12: Glypromate - Neuroprotection in CABG Surgery
Glypromate® - Neuroprotection in CABG Surgery = The first indication that Glypromate® is being tested for is neuroprotection in patients undergoing Coronary Artery Bypass (CABG) Surgery ~ During CABG surgery the heart is stopped and bypassed using a machine ~ When machine is removed and heart re-sta
Slide 13: Glypromate - Accelerated into Phase 3
Glypromate® — Accelerated into Phase 3 =» Successfully completed the preclinical program and Phase 1 clinical study ~ Safe and non-toxic; Well tolerated by humans = Currently in Phase-2a ~ Multi-centre trial for patients undergoing CABG which will complete in early CY2006 2 Pre-investigational new G
Slide 14: Glypromate - Cost effective Phase 3 study
Glypromate® - Cost effective Phase 3 study = Phase 3 trials are normally prohibitively expensive for Australian companies = Neuren’s first pivotal Phase 3 study has been structured in close consultation with the FDA and is extremely cost effective Phase 3 study in CY2006: ~ 500 patient multi- site t
Slide 15: Glypromate - Development has been significantly de-risked
Glypromate® - Development has been significantly de-risked = Why do drugs fail? ~ Safety Neuren’s development program has ~ Manufacturing The t dro ‘ret 70% demonstrated that these factors are not an OF Grugs tal issue for Glypromate® ~ Toxicology = Phase 3 study will generate efficacy data from hum
Slide 16: Agenda
Agenda ss Company Overview Lead Products - Glypromate® and NNZ 2566 Glypromate® Development Development Pipeline Commercialisation Strategy Board and Management Offer Details Conclusion i a Appendices 16 : “- Gneuren hareaciannl
Slide 17: Development pipeline
Development pipeline Glypromate® che cy2006 NNZ-2566 (IV) Yr cY2006 NNZ-2566 (Oral) CNS Product DKP’s Portfolio MC’s NRP’s GH Antagonists Growth Hormone GH Variants / Portfolio (meuren): / ohareaciiae
Slide 18: Agenda
Agenda ss Company Overview Lead Products - Glypromate® and NNZ 2566 Glypromate® Development Development Pipeline Commercialisation Strategy Board and Management Offer Details Conclusion i a Appendices 18 : “- Gneuren hareaciannl
Slide 19: Commercialisation strategy
Commercialisation strategy . * Option to secure licensing deal for Lead Products (Glypromate® Excellent Commercialisation and NNZ 2566 IV) in 2008 Prospects ~ Lucrative deal has pivotal Phase 3 efficacy trial will have been completed independently for Glypromate® s Opportunity to out-license three p
Slide 20: Significant market opportunities
Significant market opportunities » Several significant applications for both acute (short-term) and chronic (long-term) indications: Acute Indications Chronic Indications + Stroke + Alzheimer’s Disease + Coronary Artery Bypass (CABG) Surgery + Parkinson’s Disease + Traumatic Brain Injury + Multiple
Slide 21: Key commercial milestones
Key commercial milestones Glypromate® | NNZ 2566 Other Compounds Completion of Phase | Q1 Pre-clinical Phase 1 a4 NRP in vivo Q3 2a trial report cy2006 toxicology completed CY2005 programme CY2006 completes Pre-Phase 3 CMC,Tox Qi Third-stage contract Q1 DKP’s — Lead Q2 package Trial cy2006 with US D
Slide 22: Agenda
Agenda ss Company Overview Lead Products - Glypromate® and NNZ 2566 Glypromate® Development Development Pipeline Commercialisation Strategy Board and Management Offer Details Conclusion go BN, OA F CON Appendices 22 : “- Gneuren hareaciannl
Slide 23: Quality Board with direct experience in commercialising drugs
Quality Board with direct experience in commercialising drugs Neuren’s Board has Board of Directors extensive experience and Congreve (PHD) _| Leading NZ international businessman expertise in drug ier 8 development, regulatory approval and commercialisation ‘| Partner in Oceania and Eastern Group |
Slide 24: Highly experienced management and scientists
Highly experienced management and scientists Management and Scientists a Pediatrician, endocrinologist, Director of Liggins institute Former Dean, University of Auckland Medical School | World authority in neuroscience and endocrinology Formerly private UK biotech Clinical and Collaboration/JV exper
Slide 25: Executive staff experience
Executive staff experience Drugs to market in USA: 100+ years experience, 100 IND’s Atrovent for common cold, Atrovent nasal for allergic rhinitis, Combivent for COPD, Asasantin for TIAs, pameprexole for Parkinson’s, Meloxicam as a NSAID for osteoarthritis, Spiriva for COPD, Nevirapine for HIV, Flom
Slide 26: Agenda
Agenda ss Company Overview Lead Products - Glypromate® and NNZ 2566 Glypromate® Development Development Pipeline Commercialisation Strategy Board and Management Offer Details Conclusion go Sn Oo FO FF CO ON Appendices 26 : “- Gneuren hareaciannl
Slide 27: Placement
Placement Neuren Pricing Graph 30 DAY 08 VWAP 07 0.6 S DAY VWAP 0.5 0.4 0.3 0.2 ISSUE PRICE 0.1 0 Rs SS Ne Ss se & S S & ys FS FS & & Ss Fe Ry & FF FH ee wey FV PF pw vF sh Bek & o& wey = Offer of 12m shares to raise $6.36m x Attractive issue price of $0.53 ~ 12% discount to last close ~ 14% discoun
Slide 28: Use of funds
Use of funds Share Capital Structre Existing shares on issue 100,000,000 89% Placement shares 11,990,000 11% Total shares post capital raising 147,758,765 100% Market capitalisation @0.53 per share $59,254,700 Use of Funds A$000 Glypromate® pre-Phase 3 costs $2,300 Accelerated Chronic (NNZ-2566, NNZ
Slide 29: Indicative timetable
Indicative timetable Trading halt 29-30 November Dispatch of Firm Allocation Offer Letters 4 December Receipt of Firm Allocation Offer Letters 2 December Announce Placement to ASX 2 December Settlement of Placement shares 7 December Placement shares listed on ASX 8 December All queries regarding the
Slide 30: Agenda
Agenda ss Company Overview Lead Products - Glypromate® and NNZ 2566 Glypromate® Development Development Pipeline Commercialisation Strategy Board and Management Offer Details Conclusion eC), 2&2 |N Oo FF CN Appendices 30 : “- Gneuren hareaciannl
Slide 31: Investment highlights
Investment highlights Stage of Development Poised for Major Milestones Excellent Commercialisation Prospects Glypromate® accelerated to Phase 3 in CY2006 ~ Multi-site international and domestic trials NNZ 2566 is entering Phase 1 in 1H CY2006 ~ Conducted in collaboration with the US Department of De
Slide 32: Investment highlights
Investment highlights Uniquely positioned to fund lis own Phase 3 Study Significant Market Opportunities Excellent Management Team bd Breadth and qualiiy of portfolio Altractively Priced . Very few Australian companies are in Phase 3 trials: Typically prohibitively expensive Neuren in close consulta
Slide 33: Agenda
Agenda ss Company Overview Lead Products - Glypromate® and NNZ 2566 Glypromate® Development Development Pipeline Commercialisation Strategy Board and Management Offer Details Conclusion eyo nN OOo eF CON Appendices 33 : “- Gneuren hareaciannl
Slide 34: Pipeline offers excellent potential
Pipeline offers excellent potential Diketopiperazines . Small molecules that are both neuroprotectant and stimulate neurite growth for (DKPs) neurodegenerative diseases . Most advanced compound, NNZ-2591, is currently being tested in animals Growth Hormones . Growth hormone program is focused on fin
Slide 35: Limited competition
Limited competition + No drugs currently on the market Acute « Competitors are currently conducting clinical trials for CABG, Traumatic Brain Neurodegeneration [IRIUISz- UE eS + Glypromate® has a superior profile to other products in development + Current products offer minimal effectiveness Chronic
Neuren Pharmaceuticals — Investor Presentation (November 2005) on 6ix